Sangamo Therapeutics Inc (SGMO)
0.4895
-0.03
(-5.56%)
USD |
NASDAQ |
Apr 18, 16:00
0.4895
0.00 (0.00%)
After-Hours: 20:00
Sangamo Therapeutics Free Cash Flow (Quarterly): -53.21M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -53.21M |
| September 30, 2023 | -50.04M |
| June 30, 2023 | -66.25M |
| March 31, 2023 | -76.50M |
| December 31, 2022 | -64.52M |
| September 30, 2022 | -58.03M |
| June 30, 2022 | -59.43M |
| March 31, 2022 | -61.81M |
| December 31, 2021 | -55.57M |
| September 30, 2021 | -64.63M |
| June 30, 2021 | -59.83M |
| March 31, 2021 | -76.50M |
| December 31, 2020 | -8.306M |
| September 30, 2020 | 29.06M |
| June 30, 2020 | 157.07M |
| March 31, 2020 | -22.66M |
| December 31, 2019 | -27.60M |
| September 30, 2019 | -43.01M |
| June 30, 2019 | -43.38M |
| March 31, 2019 | -51.10M |
| December 31, 2018 | -68.20M |
| September 30, 2018 | -36.86M |
| June 30, 2018 | 119.29M |
| March 31, 2018 | -20.75M |
| December 31, 2017 | -17.72M |
| Date | Value |
|---|---|
| September 30, 2017 | -16.38M |
| June 30, 2017 | 55.08M |
| March 31, 2017 | -13.55M |
| December 31, 2016 | -11.99M |
| September 30, 2016 | -17.73M |
| June 30, 2016 | -16.28M |
| March 31, 2016 | -20.61M |
| December 31, 2015 | -6.777M |
| September 30, 2015 | -14.44M |
| June 30, 2015 | -9.023M |
| March 31, 2015 | -3.477M |
| December 31, 2014 | -2.153M |
| September 30, 2014 | -5.862M |
| June 30, 2014 | -8.913M |
| March 31, 2014 | 11.25M |
| December 31, 2013 | -1.694M |
| September 30, 2013 | -4.56M |
| June 30, 2013 | -5.574M |
| March 31, 2013 | -8.086M |
| December 31, 2012 | -0.137M |
| September 30, 2012 | -5.259M |
| June 30, 2012 | -6.058M |
| March 31, 2012 | 2.649M |
| December 31, 2011 | -0.203M |
| September 30, 2011 | -6.643M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-76.50M
Minimum
Mar 2021
157.07M
Maximum
Jun 2020
-37.11M
Average
-55.57M
Median
Dec 2021
Free Cash Flow (Quarterly) Benchmarks
| AIM ImmunoTech Inc | -9.956M |
| Perspective Therapeutics Inc | -9.097M |
| Protalix BioTherapeutics Inc | 3.345M |
| Electromed Inc | 3.384M |
| Armata Pharmaceuticals Inc | -10.51M |